US 11,680,263 B2
Micro-RNAS and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions
Alon Chen, Rehovot (IL); and Orna Issler, Rehovot (IL)
Assigned to Yeda Research and Development Co. Ltd., Rehovot (IL)
Filed by Yeda Research and Development Co. Ltd., Rehovot (IL)
Filed on Apr. 12, 2021, as Appl. No. 17/227,483.
Application 17/227,483 is a division of application No. 16/180,083, filed on Nov. 5, 2018, granted, now 10,975,373.
Application 16/180,083 is a division of application No. 15/111,539, granted, now 10,125,365, issued on Nov. 13, 2018, previously published as PCT/IL2015/050132, filed on Feb. 5, 2015.
Claims priority of provisional application 61/935,912, filed on Feb. 5, 2014.
Prior Publication US 2021/0230597 A1, Jul. 29, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/113 (2010.01); C12Q 1/6883 (2018.01); C12N 15/11 (2006.01); C07H 21/02 (2006.01)
CPC C12N 15/113 (2013.01) [C12N 15/111 (2013.01); C12Q 1/6883 (2013.01); C12N 2310/141 (2013.01); C12N 2320/30 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/178 (2013.01)] 9 Claims
 
1. A method of diagnosing and treating a mood disorder in a human subject in need thereof, the method comprising:
(i) measuring an expression level of a miR-135 in a biological sample of the human subject, wherein a lower expression level of said miR-135 as compared to that in a biological sample of a healthy human subject is indicative of the mood disorder; and
(ii) treating the human subject with an anti-depressant drug or a medicament for the treatment of a mood disorder when a lower expression level of said miR-135 is indicative of the mood disorder.